Thursday saw the ABPI sentence Novo Nordisk (NOVOb.CO) to two years for “serious infractions” of its code of practice.
ABPI’s response referenced a complaint on its self-regulatory body’s website that Novo Nordisk had financed LinkedIn weight management courses for health professionals without declaring its participation.
Bribing doctors to prescribe was the complaint.
Novo said it supported the “arms-length” event to ensure health professionals received accredited training.
An ABPI panel ruled that the company’s support for health professionals, including two years of weight-loss service training, was intended to promote Saxenda and benefit its users.
“Despite our displeasure, we accept. We’ll follow the ABPI Code of Practice and the pharmaceutical industry’s highest ethics “employee.
The ABPI has only been harshly sanctioned eight times in 40 years.
Novo will face audits in 2023 and 2024 to show “clear, significant, and sustained improvement” for the ABPI board to consider resuming membership after the two-year suspension.
The suspension followed Novo’s British business leader Pinder Sahota’s resignation as ABPI president last month to avoid the infringement becoming a “distraction” from the association’s “essential job” while the complaint was investigated.
Novo leads to medical weight loss.
Wealthy nations have more obesity, type 2 diabetes, and heart disease.
Weight-loss drugs Older Saxenda. Novo’s better obesity treatment, Wegovy, is being prepped for a UK launch.
Comment Template